| abstract |
Treatment of diseases and disorders related to altered neuronal excitability, especially migraine prophylaxis, mood stabilisation and convulsions, in particular the treatment of convulsions due to epilepsy, also treatment of depression or psychomotor retardation in subjects prone to seizures. Dopamine uptake inhibitors are employed, especially benzhydryloxy-ethyl piperazine derivatives, including GBR12909, GBR12935, GBR13069, GBR13098, GBR13119 and pharmaceutically acceptable salts thereof. |